Branded Legacy Advances Engineering of Air-Driven Intranasal Drug Delivery Platform
Branded Legacy's subsidiary BioLegacy Evaluative Group has begun engineering a unitary device mold for its proprietary air-driven intranasal drug delivery system, marking a significant step toward scalable production of affordable addiction treatment solutions including inhaled naloxone.
Branded Legacy, Inc. (OTC: BLEG) has initiated engineering and development of a unitary device mold for its proprietary air-driven intranasal drug delivery platform through subsidiary BioLegacy Evaluative Group Inc. This engineering milestone represents a crucial advancement toward scalable production of the company's single-use device designed for rapid, reliable therapeutic delivery, including its flagship inhaled naloxone program.
The development builds upon a September 2025 provisional patent filing and the recent opening of a GMP-compliant facility in Vancouver. This strategic progression strengthens Branded Legacy's capacity to address the ongoing opioid crisis through affordable, high-quality pharmaceutical solutions. The company's focus on innovative addiction treatment and harm reduction solutions positions this engineering advancement as potentially transformative for emergency response to opioid overdoses.
Branded Legacy operates as a forward-thinking holdings company dedicated to pioneering solutions in addiction treatment and harm reduction. Through BioLegacy Evaluative Group and strategic collaborations with leading institutions including McMaster University and Stanford University, the company drives transformative research and innovation in the pharmaceutical space. The state-of-the-art GMP manufacturing facility in Vancouver provides advanced production capabilities essential for delivering cutting-edge products to market.
The air-driven intranasal delivery platform represents a significant technological innovation in pharmaceutical administration methods. By focusing on scalable production through the engineering of unitary device molds, Branded Legacy aims to make these life-saving treatments more accessible and cost-effective for healthcare providers and emergency responders. This development comes at a critical time when opioid-related fatalities continue to pose significant public health challenges across North America.
For additional information about Branded Legacy's initiatives and corporate developments, visit https://BrandedLegacy.com. The company's progress in engineering and manufacturing capabilities underscores its commitment to addressing critical public health challenges through technological innovation and strategic partnerships with academic institutions.